Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

Ali Bazarbachi, Ariane Boumendil, Hervé Finel, Mohamad Mohty, Luca Castagna, Didier Blaise, Karl S. Peggs, Boris Afanasyev, J. L. Diez-Martin, Paolo Corradini, David Michonneau, Stephen Robinson, Gonzalo Gutiérrez García, Francesca Bonifazi, Ibrahim Yakoub-Agha, Zafer Gülbas, Adrian Bloor, Jeremy Delage, Albert Esquirol, Ram MalladiChristof Scheid, Jean El-Cheikh, Hervé Ghesquières, Silvia Montoto, Peter Dreger, Anna Sureda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. Methods: The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation–participating centers between 2010 and 2014. Results: Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65% vs 46%) or posttransplant donor lymphocyte infusion (66% vs 33%). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29%, a partial response rate of 45%, and a stable disease rate of 26%. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P<.001), approximately 34% of the original BV cohort were alive and in CR at the time of last follow-up versus 18% in the group that did not receive BV (P=.003). The use of BV before donor lymphocyte infusion was found to be associated with the highest probability of being alive and in CR (40%) at the time of last follow-up. Salvage BV appeared to have no effect on chronic graft-versus-host disease or 1-year overall survival from the time of disease recurrence after allo-SCT (76% vs 67%). Conclusions: BV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo-SCT, even after prior exposure to BV.

Original languageEnglish
Pages (from-to)90-98
Number of pages9
JournalCancer
Volume125
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Lymphoma
Stem Cell Transplantation
Salvage Therapy
cAC10-vcMMAE
Recurrence
Tissue Donors
Lymphocytes
Graft vs Host Disease
Disease Progression

Keywords

  • allogeneic stem cell transplantation (allo-SCT)
  • brentuximab vedotin
  • donor lymphocyte infusion
  • Hodgkin lymphoma
  • recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation : A report from the EBMT Lymphoma Working Party. / Bazarbachi, Ali; Boumendil, Ariane; Finel, Hervé; Mohty, Mohamad; Castagna, Luca; Blaise, Didier; Peggs, Karl S.; Afanasyev, Boris; Diez-Martin, J. L.; Corradini, Paolo; Michonneau, David; Robinson, Stephen; Gutiérrez García, Gonzalo; Bonifazi, Francesca; Yakoub-Agha, Ibrahim; Gülbas, Zafer; Bloor, Adrian; Delage, Jeremy; Esquirol, Albert; Malladi, Ram; Scheid, Christof; El-Cheikh, Jean; Ghesquières, Hervé; Montoto, Silvia; Dreger, Peter; Sureda, Anna.

In: Cancer, Vol. 125, No. 1, 01.01.2019, p. 90-98.

Research output: Contribution to journalArticle

Bazarbachi, A, Boumendil, A, Finel, H, Mohty, M, Castagna, L, Blaise, D, Peggs, KS, Afanasyev, B, Diez-Martin, JL, Corradini, P, Michonneau, D, Robinson, S, Gutiérrez García, G, Bonifazi, F, Yakoub-Agha, I, Gülbas, Z, Bloor, A, Delage, J, Esquirol, A, Malladi, R, Scheid, C, El-Cheikh, J, Ghesquières, H, Montoto, S, Dreger, P & Sureda, A 2019, 'Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party', Cancer, vol. 125, no. 1, pp. 90-98. https://doi.org/10.1002/cncr.31755
Bazarbachi, Ali ; Boumendil, Ariane ; Finel, Hervé ; Mohty, Mohamad ; Castagna, Luca ; Blaise, Didier ; Peggs, Karl S. ; Afanasyev, Boris ; Diez-Martin, J. L. ; Corradini, Paolo ; Michonneau, David ; Robinson, Stephen ; Gutiérrez García, Gonzalo ; Bonifazi, Francesca ; Yakoub-Agha, Ibrahim ; Gülbas, Zafer ; Bloor, Adrian ; Delage, Jeremy ; Esquirol, Albert ; Malladi, Ram ; Scheid, Christof ; El-Cheikh, Jean ; Ghesquières, Hervé ; Montoto, Silvia ; Dreger, Peter ; Sureda, Anna. / Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation : A report from the EBMT Lymphoma Working Party. In: Cancer. 2019 ; Vol. 125, No. 1. pp. 90-98.
@article{c2f12effa7684370875381b8c2db316e,
title = "Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party",
abstract = "Background: The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. Methods: The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation–participating centers between 2010 and 2014. Results: Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65{\%} vs 46{\%}) or posttransplant donor lymphocyte infusion (66{\%} vs 33{\%}). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29{\%}, a partial response rate of 45{\%}, and a stable disease rate of 26{\%}. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P<.001), approximately 34{\%} of the original BV cohort were alive and in CR at the time of last follow-up versus 18{\%} in the group that did not receive BV (P=.003). The use of BV before donor lymphocyte infusion was found to be associated with the highest probability of being alive and in CR (40{\%}) at the time of last follow-up. Salvage BV appeared to have no effect on chronic graft-versus-host disease or 1-year overall survival from the time of disease recurrence after allo-SCT (76{\%} vs 67{\%}). Conclusions: BV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo-SCT, even after prior exposure to BV.",
keywords = "allogeneic stem cell transplantation (allo-SCT), brentuximab vedotin, donor lymphocyte infusion, Hodgkin lymphoma, recurrence",
author = "Ali Bazarbachi and Ariane Boumendil and Herv{\'e} Finel and Mohamad Mohty and Luca Castagna and Didier Blaise and Peggs, {Karl S.} and Boris Afanasyev and Diez-Martin, {J. L.} and Paolo Corradini and David Michonneau and Stephen Robinson and {Guti{\'e}rrez Garc{\'i}a}, Gonzalo and Francesca Bonifazi and Ibrahim Yakoub-Agha and Zafer G{\"u}lbas and Adrian Bloor and Jeremy Delage and Albert Esquirol and Ram Malladi and Christof Scheid and Jean El-Cheikh and Herv{\'e} Ghesqui{\`e}res and Silvia Montoto and Peter Dreger and Anna Sureda",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cncr.31755",
language = "English",
volume = "125",
pages = "90--98",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation

T2 - A report from the EBMT Lymphoma Working Party

AU - Bazarbachi, Ali

AU - Boumendil, Ariane

AU - Finel, Hervé

AU - Mohty, Mohamad

AU - Castagna, Luca

AU - Blaise, Didier

AU - Peggs, Karl S.

AU - Afanasyev, Boris

AU - Diez-Martin, J. L.

AU - Corradini, Paolo

AU - Michonneau, David

AU - Robinson, Stephen

AU - Gutiérrez García, Gonzalo

AU - Bonifazi, Francesca

AU - Yakoub-Agha, Ibrahim

AU - Gülbas, Zafer

AU - Bloor, Adrian

AU - Delage, Jeremy

AU - Esquirol, Albert

AU - Malladi, Ram

AU - Scheid, Christof

AU - El-Cheikh, Jean

AU - Ghesquières, Hervé

AU - Montoto, Silvia

AU - Dreger, Peter

AU - Sureda, Anna

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. Methods: The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation–participating centers between 2010 and 2014. Results: Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65% vs 46%) or posttransplant donor lymphocyte infusion (66% vs 33%). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29%, a partial response rate of 45%, and a stable disease rate of 26%. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P<.001), approximately 34% of the original BV cohort were alive and in CR at the time of last follow-up versus 18% in the group that did not receive BV (P=.003). The use of BV before donor lymphocyte infusion was found to be associated with the highest probability of being alive and in CR (40%) at the time of last follow-up. Salvage BV appeared to have no effect on chronic graft-versus-host disease or 1-year overall survival from the time of disease recurrence after allo-SCT (76% vs 67%). Conclusions: BV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo-SCT, even after prior exposure to BV.

AB - Background: The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. Methods: The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation–participating centers between 2010 and 2014. Results: Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65% vs 46%) or posttransplant donor lymphocyte infusion (66% vs 33%). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29%, a partial response rate of 45%, and a stable disease rate of 26%. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P<.001), approximately 34% of the original BV cohort were alive and in CR at the time of last follow-up versus 18% in the group that did not receive BV (P=.003). The use of BV before donor lymphocyte infusion was found to be associated with the highest probability of being alive and in CR (40%) at the time of last follow-up. Salvage BV appeared to have no effect on chronic graft-versus-host disease or 1-year overall survival from the time of disease recurrence after allo-SCT (76% vs 67%). Conclusions: BV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo-SCT, even after prior exposure to BV.

KW - allogeneic stem cell transplantation (allo-SCT)

KW - brentuximab vedotin

KW - donor lymphocyte infusion

KW - Hodgkin lymphoma

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=85055479928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055479928&partnerID=8YFLogxK

U2 - 10.1002/cncr.31755

DO - 10.1002/cncr.31755

M3 - Article

C2 - 30351488

AN - SCOPUS:85055479928

VL - 125

SP - 90

EP - 98

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -